Alps Advisors Inc. raised its position in shares of bluebird bio, Inc. (NASDAQ:BLUE) by 21.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 44,898 shares of the biotechnology company’s stock after purchasing an additional 7,936 shares during the period. Alps Advisors Inc. owned 0.10% of bluebird bio worth $6,167,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Hanseatic Management Services Inc. raised its stake in shares of bluebird bio by 0.3% in the 2nd quarter. Hanseatic Management Services Inc. now owns 10,436 shares of the biotechnology company’s stock valued at $1,096,000 after acquiring an additional 27 shares in the last quarter. Teacher Retirement System of Texas raised its stake in shares of bluebird bio by 1.7% in the 2nd quarter. Teacher Retirement System of Texas now owns 3,250 shares of the biotechnology company’s stock valued at $341,000 after acquiring an additional 53 shares in the last quarter. Cornerstone Capital Management Holdings LLC. raised its stake in shares of bluebird bio by 0.8% in the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 17,955 shares of the biotechnology company’s stock valued at $1,885,000 after acquiring an additional 140 shares in the last quarter. Prudential Financial Inc. raised its stake in shares of bluebird bio by 4.0% in the 2nd quarter. Prudential Financial Inc. now owns 3,882 shares of the biotechnology company’s stock valued at $408,000 after acquiring an additional 150 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in shares of bluebird bio by 0.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,433 shares of the biotechnology company’s stock valued at $3,302,000 after acquiring an additional 151 shares in the last quarter.

Shares of bluebird bio, Inc. (NASDAQ:BLUE) traded up $1.40 during mid-day trading on Friday, reaching $151.75. The company had a trading volume of 482,700 shares, compared to its average volume of 854,275. bluebird bio, Inc. has a twelve month low of $53.50 and a twelve month high of $164.80.

bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.68) by ($0.05). The company had revenue of $7.71 million during the quarter, compared to analyst estimates of $8.47 million. bluebird bio had a negative net margin of 883.18% and a negative return on equity of 28.79%. bluebird bio’s quarterly revenue was up 397.4% compared to the same quarter last year. During the same period in the prior year, the firm earned ($2.07) EPS. equities analysts forecast that bluebird bio, Inc. will post -6.68 earnings per share for the current year.

In other bluebird bio news, Director James Mandell sold 1,000 shares of bluebird bio stock in a transaction on Monday, August 14th. The stock was sold at an average price of $95.95, for a total value of $95,950.00. Following the completion of the transaction, the director now owns 1,000 shares in the company, valued at approximately $95,950. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Daniel Lynch sold 500 shares of bluebird bio stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $120.00, for a total value of $60,000.00. Following the completion of the transaction, the director now owns 3,300 shares of the company’s stock, valued at approximately $396,000. The disclosure for this sale can be found here. In the last ninety days, insiders sold 184,268 shares of company stock worth $24,173,111. 3.90% of the stock is owned by insiders.

A number of brokerages recently weighed in on BLUE. SunTrust Banks, Inc. raised their price objective on bluebird bio from $108.00 to $163.00 and gave the company a “buy” rating in a research note on Friday, November 3rd. Jefferies Group LLC reissued a “hold” rating and issued a $130.00 price objective on shares of bluebird bio in a research note on Friday, November 3rd. Morgan Stanley raised bluebird bio from an “underweight” rating to an “equal weight” rating in a research note on Friday, November 3rd. Barclays PLC raised their price objective on bluebird bio from $151.00 to $162.00 and gave the company an “overweight” rating in a research note on Thursday, November 2nd. Finally, Maxim Group reissued a “buy” rating and issued a $170.00 price objective on shares of bluebird bio in a research note on Thursday, November 2nd. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and fourteen have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $131.05.

ILLEGAL ACTIVITY WARNING: “Alps Advisors Inc. Purchases 7,936 Shares of bluebird bio, Inc. (BLUE)” was reported by Watch List News and is the property of of Watch List News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.watchlistnews.com/alps-advisors-inc-purchases-7936-shares-of-bluebird-bio-inc-blue/1698233.html.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio, Inc. (NASDAQ:BLUE).

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.